PHOENIX, May 10, 2017 /PRNewswire/ -- Melanin and Ocular Lens Pigment are natural defenses to filter Blue light in skin and eyes. Innovative external lenses using these derivatized compounds complement the human body to reduce glare, improve sleep, balance circadian rhythm to maintain overall health, and may prevent blindness.
On April 13, 2017, Dr. Michael Tolentino MD delivered the prestigious "Jacob Moses MD Memorial Lectureship" to an audience of over 40 eye doctors in Columbus Ohio regarding the impact of naturally occurring and artificially generated sources of High Energy Visible (Blue) light on the primary optical tract and retinal-hypothalamic tract. "Blue light threatens our eyes, our vision, and circadian rhythm," explained Dr. Tolentino. He detailed preventative measures to protect our visual and physiological systems using cost-effective external lenses to enhance natural defenses.
The human body produces Melanin and Ocular Lens Pigment, which were paradigms for Blue light protection, and patented by Dr. James Gallas of Photoprotective Technologies as derivatives that filter light in proportion to the Blue light wavelengths ability to cause damage.
"The combination of Melanin and Ocular Lens Pigment (OLPTM) provide more effective filtration of Blue light than anything I am aware of and I recommend using the lenses to reduce issues involving glare and damage to the retina and macula from prolonged or intense Blue light exposure. Further, the MPF lens promotes balanced Melatonin production, critical to proper physiological function to help mitigate chronic diseases including cardiovascular issues, depression, diabetes, obesity, and cancer," explained Dr. Tolentino.
TrueBlue Vision holds the exclusive production of lenses and products for both natural (outdoor) and artificial (indoor) blue light filtration. After an extensive review of product performance, TrueBlue was recently chosen by "IRIS The Visual Group" Canada's largest network of Eyecare Professionals.
The Jacob Moses MD Lectureship was established with gifts made in his memory from his son, Dr. James L. Moses, MD and other family members. A distinguished Ophthalmologist for 58 years, Dr. Jacob Moses was a pioneer and leader in ophthalmology in Ohio. He was a family man, known as a compassionate contributing individual, physician, and educator whose thoroughness, tenacity and endurance were unequaled. The Lectureship is an annual event and invites luminaries in the field of ophthalmology to speak to the Columbus Ohio ophthalmic community.
Dr. Michael Tolentino an Associate Professor of Clinical Ophthalmology at the University of Central Florida and co-founder of the Tolentino Eye Research Foundation (www.tolentinoeye.org) is recognized globally as a medical authority, whose qualifications include education or faculty at Brown University, Harvard University, University of Massachusetts and University of Pennsylvania. He co- invented the concept of intravitreal anti-Vascular Endothelial Growth Factor (VEGF) injections, in particular, the drug Avastin. He is credited for determining that VEGF is sufficient and necessary for the development of diseases such as diabetic retinopathy and wet macular degeneration. He also co-invented Bevasiranib a siRNA against VEGF. As a clinical trialist, he has helped more than half a dozen drugs or treatments for the eye obtain FDA approval. He is currently developing novel topical, nutritional, and preventative alternatives to prevent blindness.
To learn more about preventative strategies and novel therapies for retinal diseases such as macular degeneration and diabetic retinopathy, please visit http://www.tolentinoeye.org or contact firstname.lastname@example.org
To learn more about the Blue Light Threat and TrueBlue lenses, please visit http://www.truebluevision.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/a-jacob-moses-md-memorial-lecture-offers-a-new-perspective-on-blue-light-and-innovative-technology-to-prevent-disease-while-enhancing-visual-performance-300455186.html
SOURCE TrueBlue Vision